PARPi after PARPi in epithelial ovarian cancer
The objective of this study was to describe the treatment experience of patients with recurrent epithelial ovarian cancer who are retreated with an inhibitor of poly(ADP-ribose)-polymerase (PARPi). We conducted a multi-institutional, retrospective review of ovarian cancer patients who received ≥2 li...
Saved in:
Main Authors: | K.G. Essel (Author), K. Behbakht (Author), T. Lai (Author), L. Hand (Author), E. Evans (Author), J. Dvorak (Author), K. Ding (Author), G. Konecny (Author), K.N. Moore (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
by: Malak Moubarak, et al.
Published: (2022) -
Fully Automated, High-Dose Radiosynthesis of [<sup>18</sup>F]PARPi
by: Anna Pacelli, et al.
Published: (2022) -
Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials
by: Martina Panebianco, et al.
Published: (2024) -
Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification
by: George Nassief, BA, et al.
Published: (2024) -
Correction: Pacelli et al. Fully Automated, High-Dose Radiosynthesis of [18F]PARPi. <i>Pharmaceuticals</i> 2022, <i>15</i>, 865
by: Anna Pacelli, et al.
Published: (2023)